Yang Qiwen, Zhang Hui, Wang Yao, Xu Zhipeng, Zhang Ge, Chen Xinxin, Xu Yingchun, Cao Bin, Kong Haishen, Ni Yuxing, Yu Yunsong, Sun Ziyong, Hu Bijie, Huang Wenxiang, Wang Yong, Wu Anhua, Feng Xianju, Liao Kang, Luo Yanping, Hu Zhidong, Chu Yunzhuo, Lu Juan, Su Jianrong, Gui Bingdong, Duan Qiong, Zhang Shufang, Shao Haifeng, Badal Robert E
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Department of Respiratory and Critical Care Medicine, Clinical Microbiology and Infectious Disease Lab., China-Japan Friendship Hospital, Beijing, 100029, China.
BMC Infect Dis. 2017 Mar 6;17(1):192. doi: 10.1186/s12879-017-2296-x.
The objective of this study was to investigate the distribution and susceptibility of aerobic and facultative Gram-negative bacilli isolated from Chinese patients with UTIs collected within 48 h (community acquired, CA) or after 48 h (hospital acquired, HA) of hospital admission.
From 2010 to 2014, the minimum inhibitory concentrations (MICs) of 12 antibiotics for 4,332 aerobic and facultative Gram-negative bacilli, sampled in 21 hospitals in 16 cities, were determined by the broth microdilution method.
Enterobacteriaceae composed 88.5% of the total isolates, with Escherichia coli (E. coli) (63.2%) the most commonly isolated species, followed by Klebsiella pneumoniae (K. pneumoniae) (12.2%). Non-Enterobacteriaceae accounted for only 11.5% of all isolates and included mainly Pseudomonas aeruginosa (P. aeruginosa) (6.9%) and Acinetobacter baumannii (A. baumannii) (3.3%). Among the antimicrobial agents tested, the susceptibility rates of E.coli to the two carbapenems, ertapenem and imipenem as well as amikacin and piperacillin-tazobactam ranged from 92.5 to 98.7%. Against K. pneumonia, the most potent antibiotics were imipenem (92.6% susceptibility), amikacin (89.2% susceptibility) and ertapenem (87.9% susceptibility). Although non-Enterobacteriaceae did not show high susceptibilities to the 12 common antibiotics, amikacin exhibited the highest in vitro activity against P. aeruginosa over the 5-year study period, followed by piperacillin-tazobactam, imipenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin. The Extended Spectrum Beta-Lactamase (ESBL) rates decreased slowly during the 5 years in E. coli from 68.6% in 2010 to 59.1% in 2014, in K. pneumoniae from 59.7 to 49.2%, and in Proteus mirabilis (P. mirabilis) from 40.0 to 26.1%. However, the ESBL rates were different in 5 regions of China (Northeast, North, East, South and Middle-China).
E. coli and K. pneumonia were the major pathogens causing UTIs and carbapenems and amikacin retained the highest susceptibility rates over the 5-year study period, indicating that they are good drug choices for empirical therapies, particularly of CA UTIs in China.
本研究的目的是调查从中国尿路感染(UTIs)患者中分离出的需氧和兼性革兰氏阴性杆菌的分布及药敏情况,这些患者是在入院48小时内(社区获得性,CA)或48小时后(医院获得性,HA)采集的样本。
2010年至2014年期间,采用肉汤微量稀释法测定了来自16个城市21家医院的4332株需氧和兼性革兰氏阴性杆菌对12种抗生素的最低抑菌浓度(MICs)。
肠杆菌科细菌占分离菌总数的88.5%,其中大肠埃希菌(E. coli)(63.2%)是最常见的分离菌种,其次是肺炎克雷伯菌(K. pneumoniae)(12.2%)。非肠杆菌科细菌仅占所有分离菌的11.5%,主要包括铜绿假单胞菌(P. aeruginosa)(6.9%)和鲍曼不动杆菌(A. baumannii)(3.3%)。在所测试的抗菌药物中,大肠埃希菌对两种碳青霉烯类药物(厄他培南和亚胺培南)以及阿米卡星和哌拉西林 - 他唑巴坦的药敏率在92.5%至98.7%之间。对于肺炎克雷伯菌,最有效的抗生素是亚胺培南(药敏率92.6%)、阿米卡星(药敏率89.2%)和厄他培南(药敏率87.9%)。虽然非肠杆菌科细菌对这12种常用抗生素的药敏率不高,但在为期5年的研究期间,阿米卡星对铜绿假单胞菌的体外活性最高,其次是哌拉西林 - 他唑巴坦、亚胺培南、头孢他啶、头孢吡肟、环丙沙星和左氧氟沙星。在5年期间,大肠埃希菌的超广谱β-内酰胺酶(ESBL)率从2010年的68.6%缓慢下降至2014年的59.1%,肺炎克雷伯菌从59.7%降至49.2%,奇异变形杆菌(P. mirabilis)从40.0%降至26.1%。然而,中国5个地区(东北、华北、华东、华南和华中)的ESBL率有所不同。
大肠埃希菌和肺炎克雷伯菌是引起UTIs的主要病原体,在为期5年的研究期间,碳青霉烯类药物和阿米卡星的药敏率最高,表明它们是经验性治疗的良好药物选择,尤其是在中国的社区获得性UTIs治疗中。